Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN versus NIZORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN versus NIZORAL.
GYNE-LOTRIMIN vs NIZORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Intravaginal: clotrimazole 500 mg vaginal tablet once or 200 mg vaginal tablet daily for 3 days or 1% vaginal cream 5 g daily for 7–14 days. Topical: clotrimazole 1% cream applied to affected area twice daily for 2–4 weeks.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
None Documented
None Documented
The terminal elimination half-life of clotrimazole is approximately 3.5-4.9 hours. However, after topical application, systemic absorption is minimal, and local concentrations persist for hours to days at the site of action.
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; renal excretion accounts for <1% of absorbed dose.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal